CClinicalTrials.gg
RecruitingNCT07767682Updated Aug 17, 2026

Effect of Oxidized Regenerated Cellulose on Vestibular Sulcus Depth After Clark Vestibuloplasty

An interventional study of Oxidized Regenerated Cellulose (ORC) and Periodontal Dressing in Insufficient Vestibular Sulcus Depth, sponsored by Izmir Katip Celebi University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Izmir Katip Celebi University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This randomized controlled clinical study will evaluate whether the use of oxidized regenerated cellulose (Reoxcel Sigma Knit) in addition to standard Clark vestibuloplasty improves vestibular sulcus depth and patient comfort in individuals with insufficient vestibular depth. A total of 36 participants will be assigned to either Clark vestibuloplasty with oxidized regenerated cellulose or standard Clark vestibuloplasty with periodontal dressing. Vestibular sulcus depth and keratinized gingival tissue will be assessed before treatment and at 1 and 3 months after surgery. Postoperative pain and analgesic use will also be evaluated during the first 7 days after surgery.

02

Conditions studied

  • Insufficient Vestibular Sulcus Depth

Keywords

  • vestibuloplasty
  • Clark vestibuloplasty
  • oxidized regenerated cellulose
  • vestibular sulcus depth
  • keratinized gingiva
03

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Systemically healthy
  • Non-smoker
  • Insufficient vestibular sulcus depth
  • No regular medication use
  • Age 18 years or older
  • No previous vestibuloplasty in the same region
  • Not pregnant or breastfeeding
  • Willing to participate and able to provide written informed consent

Exclusion criteria

Exclusion Criteria:

  • Presence of a systemic disease
  • Regular use of systemic medication
  • Pregnancy or lactation
  • Smoking or alcohol use
  • Previous vestibuloplasty in the same region
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Clark Vestibuloplasty + Oxidized Regenerated Cellulose

    Participants in this arm will undergo standard Clark vestibuloplasty. In addition, oxidized regenerated cellulose (Reoxcel Sigma Knit) will be applied over the surgical wound in a double layer and secured with sutures.

    Device: Oxidized Regenerated Cellulose (ORC)

  • Active comparator
    Standard Clark Vestibuloplasty

    Participants in this arm will undergo standard Clark vestibuloplasty. Following surgery, the exposed gingival wound surface will be covered with a periodontal dressing (Coe-Pak) without the application of oxidized regenerated cellulose.

    Device: Periodontal Dressing

Interventions

  • DeviceOxidized Regenerated Cellulose (ORC)

    Oxidized regenerated cellulose (Reoxcel Sigma Knit, 5 × 7.5 cm) will be applied in a double layer over the exposed gingival wound surface following standard Clark vestibuloplasty. The material will be secured with 4-0 polyglycolide-lactide sutures using crossed and simple suturing techniques.

  • DevicePeriodontal Dressing

    Periodontal dressing (Coe-Pak) will be applied over the exposed gingival wound surface following standard Clark vestibuloplasty. The dressing will cover the surgical site during the postoperative healing period.

05

What researchers measure

Primary outcomes

  1. Change in Vestibular Sulcus Depth

    Vestibular sulcus depth will be measured using a UNC-15 periodontal probe from the gingival margin to the deepest point of the vestibular sulcus. Measurements will be recorded before surgery and repeated at follow-up visits to evaluate the change in vestibular sulcus depth.

    Time frame: Baseline, 1 month, and 3 months after surgery

Secondary outcomes

  1. Postoperative Pain Assessed by Visual Analog Scale (VAS)

    Postoperative pain intensity will be assessed using a Visual Analog Scale ranging from 0 (no pain) to 10 (unbearable pain). Participants will record their pain score daily after surgery.

    Time frame: Daily for 7 days after surgery

  2. Postoperative Pain Assessed by Wong-Baker Faces Pain Rating Scale

    Postoperative pain will be assessed using the Wong-Baker Faces Pain Rating Scale, which consists of six facial expressions ranging from a happy face representing no pain to a distressed face representing the worst pain. At the end of each day, participants will select the face that best represents the pain they experienced that day.

    Time frame: Daily for 7 days after surgery

  3. Postoperative Analgesic Consumption

    Participants will record the number of analgesic tablets taken each day after surgery. Total analgesic consumption will be used to compare postoperative discomfort between the study groups.

    Time frame: Daily for 7 days after surgery

06

Study locations

1 of 1 sites recruiting
  • İzmir Katip Çelebi University
    Izmir, Çiğli 35620, Turkey (Türkiye)
    • Can Berk Arığ · Contact · canberkarig@gmail.com · +90 534 060 64 57
    • Can Berk Arığ, Research Assistant · Principal investigator
    • Mehmet Sağlam, Professor · Sub investigator
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07767682
Lead sponsor
Izmir Katip Celebi University
Responsible party
Can Berk Arig (Research Assistant, Izmir Katip Celebi University) — Principal investigator
First posted
Aug 17, 2026
Start date
Apr 9, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Aug 17, 2026

Study contacts

Can Berk Arığ
Contact
canberkarig@gmail.com
+90 534 060 64 57

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion